Home › Funds › Omega Fund Management, LLC › BBOT

Omega Fund Management, LLC position in BBOT

BridgeBio Oncology Therapeutic Inc · Health Care

Omega Fund Management, LLC reported holding 3,289,661 shares of BBOT (BridgeBio Oncology Therapeutic Inc) in its Q2 2026 13F filing — a position valued at US$25.1M, representing 13.50% of its reported portfolio and ranking #4 among its reported holdings. Omega Fund Management, LLC has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)3.29M sh
Reported value held$25.07M
Portfolio Weight13.50%
First reportedQ3 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Omega Fund Management, LLC's BBOT position evolved

Omega Fund Management, LLC first disclosed a stake in BBOT in Q3 2025 at 3,289,661 shares (US$38.1M). The position peaked in Q4 2025 at 3,289,661 shares, worth US$41.2M. Across 4 filings, Omega Fund Management, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 3,289,661 shares valued at US$25.1M.

Quarter by quarter

QuarterSharesValueChange
Q3 2025 3.29M $38.09M New
Q4 2025 3.29M $41.19M Hold
Q1 2026 3.29M $29.44M Hold
Q2 2026 3.29M $25.07M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BBOT and 13F data

BBOT (BridgeBio Oncology Therapeutic Inc) is a Health Care company. 74 other funds we track also report a position in BBOT — the largest reported positions include Cormorant Asset Management, LP (US$136.2M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$37.2M), Alphabet Inc. (US$21.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BBOT

All BBOT fund holders →

FAQ

How long has Omega Fund Management, LLC held BBOT?

Omega Fund Management, LLC has disclosed BBOT holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is Omega Fund Management, LLC's current position in BBOT?

As of Q2 2026, Omega Fund Management, LLC holds 3.29M shares of BBOT (BridgeBio Oncology Therapeutic Inc), valued at $25.07M, representing 13.50% of its reported portfolio and ranking #4.

Has Omega Fund Management, LLC been buying or selling BBOT?

In the latest 13F filing (Q2 2026), Omega Fund Management, LLC held unchanged its position in BBOT. The position peaked in Q4 2025 at 3.29M shares.

Which other funds hold BBOT?

Other major institutional holders of BBOT include Cormorant Asset Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Alphabet Inc., among 74 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.